search
Back to results

Laparoscopic Ventral Hernia Repair With Routine Defect Closure Using Su2ura® Approximation Device

Primary Purpose

Ventral Hernia

Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Hernia repair surgery using the Su2ura® approximation device
Physical Examination
Vital Signs
Blood Tests
Urine Pregnancy Test
Abdominal Ultrasound imaging
EuraHS-QoL
Visual Analouge Scale (VAS)
Clinical evaluation for hernia recurrence and clinical bulging
Sponsored by
Anchora Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ventral Hernia focused on measuring hernia, primary, ventral, laparoscopy, umbilical

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥18 years.
  2. Patient desires an elective surgical repair.
  3. Patient is able to provide an informed consent.
  4. Diagnosis of a primary or secondary ventral hernia, with a fascial defect of width no more than 5 cm width in size on clinical examination or imaging scan.
  5. Body mass index (BMI) of 20-40 kg/m2.
  6. Candidate for laparoscopic repair based on the operating surgeon's assessment.

Exclusion Criteria:

Exclusion criteria 1. Diagnosis of concomitant abdominal wall defect(s) contiguous with ventral hernia.

2. Patient in need of concomitant non-hernia repair surgical procedure(s). 3. Patient in need of emergent ventral hernia repair for complications such as incarceration, intestinal obstruction or strangulation.

4. The patient desires hernia repair using a technique other than that consistent with the study.

5. Patient has loss of domain as assessed on physical examination or CT scan. 6. Patient has a history of an abdominal aortic aneurysm repair. 7. Patient has a severe co-morbid condition likely to limit survival to less than 2 years.

8. Patient was treated with chemotherapy in the past 6 months. 9. Patient was treated with steroids in the past 6 months. 10. Patient with known collagen disorder. 11. Clean contaminated/contaminated or dirty surgical field. 12. Patient is pregnant or intends to become pregnant during the study period. 13. Patient has ascites on physical examination or CT scan. 14. Patient has liver failure. 15. Patient undergoing dialysis treatment. 16. Patient has a wound-healing disorder. 17. Patient has an untreated coagulation disorder or is on anti-coagulant therapy not managed peri-operatively with the advice or supervision of a hematologist.

18. Patient with autoimmune disorder requiring more than 10 mg of corticosteroid daily.

19. Patient who is immunocompromised (including a diagnosis of HIV/AIDS, organ transplant, or receiving chemo- or radiation therapy.

20. Patient in need of concomitant surgical procedures other than indicated in the protocol as acceptable.

21. Non-compliance with the study protocol. 22. Patient requests to exit the study. 23. Prior radiotherapy. 24. Active malignancy for at least 2 years. 25. Patients has Diastasis recti more than 4cm×4cm size

Sites / Locations

  • Hillel Yaffe Medical CenterRecruiting
  • Barzilai Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Su2ura® approximation device - study device group

Arm Description

Patients with a primary umbilical hernia will be recruited to the study and the hernia will be repaired using the Su2ura® approximation device

Outcomes

Primary Outcome Measures

Adverse events assesments
Overall rate of Serious Adverse Events and serious adverse device effects (SADE) related to study product up to hospital discharge and up to the 30th post-operative day.

Secondary Outcome Measures

Hernia recurrence rate
Hernia recurrence rate (Investigator confirmed hernia recurrence on physical examination or imaging).
Patient satisfaction
2. Patient satisfaction and function as assessed by the European Hernia Society Quality of life questionnaire (EuraHS-QoL). score range : 0-180 pts; higher score means high pain and discomfort levels.

Full Information

First Posted
July 27, 2021
Last Updated
July 20, 2023
Sponsor
Anchora Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT04986917
Brief Title
Laparoscopic Ventral Hernia Repair With Routine Defect Closure Using Su2ura® Approximation Device
Official Title
Laparoscopic Ventral Hernia Repair With Routine Defect Closure Using Su2ura® Approximation Device
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2022 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Anchora Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Study includes 5 visits: Screening, Baseline/Surgery, and 14 days, 3 months, 12months Follow-Ups post-surgery. The actual point of enrollment for each subject is considered the day of surgery. Total study duration is up to 12 months post-surgery. Surgery will be performed under general anesthesia. Standard antibiotic prophylaxis will be administered 30 min prior to skin incision. A surgical assistant will be selected by the PI from the surgical staff of the department. The procedure will involve placement of laparoscopic ports, reduction of the hernia sac, closure of the defect with the Su2ura® approximation device and fixation of mesh with tacks over the closed defect in an IPOM fashion. Based on surgeon consideration, primary umbilical hernia defects under 2 cm will be repaired with or without mesh. Study follow-up visits will take place 14 days, 3 months and 12 months post-surgery.
Detailed Description
This study will be performed in accordance with the design and specific provisions of this protocol, in accordance with the ethical principles that have their origin in the Declaration of Helsinki, that are consistent with Good Clinical Practice (GCP), Title 21 of the Code of Federal Regulations (21 CFR), part 812 (Investigational Device Exemptions), and the applicable regulatory requirements. The study is a prospective, multi-center, open study, to evaluate the efficacy and safety of the Su2ura® approximation device. An abdominal hernia emerges through a preformed or acquired defect of the abdominal wall. The defect may be congenital (primary), acquired as a result of wear and tear (primary), or result from surgery or trauma, where failure of the abdominal wall to heal produces an incisional (non-primary) hernia. Examples of abdominal hernia include epigastric, umbilical and inguinal hernia. Patients may be asymptomatic or complain of a lump or pain. These patients are offered elective surgery. Patients may also present with complications necessitating emergency repair with or without additional resection of compromised viscera. Ventral hernias are very common and do present a challenge because of the risk of recurrence. Besides the surgeon, these hernias are ideally managed by a dietitian, nurse, and a physical therapist. Patient education has been a very popular topic in literature and hospital settings. Giving patients literature and discussing outcomes with instructions on multiple aspects throughout their encounters has shown to be very effective. The Su2ura Approximation Device is designed to deploy anchors threaded with stiches to facilitate tissue approximation by eliminating the need for the passing of a needle from one side of the tissue to the other as performed in traditional suturing. Utilizing the anchor feature allows a single action placement of a suture. The principal investigator from each medical center participated in an appropriate training program. This training included the surgery procedure in an animal. The Principal investigators will train the sub investigators in this procedure. The sponsor will also provide training on the laparoscopic simulator to the principal investigators. A total of 60 patients will be recruited to the study. Patients with a primary umbilical hernia under 2 cm will be recruited to the study and the hernia will be repaired with or without mesh according to the PI's decision. Eligible patients with a primary or secondary ventral hernia, desiring an elective surgical repair, who amply the inclusion/Exclusion criteria will be offered to participate in the study. Study includes 5 visits: Screening, Baseline/Surgery, and 14 days, 3 months, 12months Follow-Ups post-surgery. The actual point of enrollment for each subject is considered the day of surgery. Total study duration is up to 12months post-surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventral Hernia
Keywords
hernia, primary, ventral, laparoscopy, umbilical

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A total of 60 patients will be recruited to the study. Patients with a primary umbilical hernia under 2 cm will be recruited to the study and the hernia will be repaired with or without mesh according to the PI's decision. Eligible patients with a primary or secondary ventral hernia, desiring an elective surgical repair, who amply the inclusion/Exclusion criteria will be offered to participate in the study. Study includes 5 visits: Screening, Baseline/Surgery, and 14 days, 3 months, 12months Follow-Ups post-surgery. The actual point of enrollment for each subject is considered the day of surgery. Total study duration is up to 12months post-surgery.
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Su2ura® approximation device - study device group
Arm Type
Experimental
Arm Description
Patients with a primary umbilical hernia will be recruited to the study and the hernia will be repaired using the Su2ura® approximation device
Intervention Type
Device
Intervention Name(s)
Hernia repair surgery using the Su2ura® approximation device
Other Intervention Name(s)
study device intervention
Intervention Description
. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
Intervention Type
Diagnostic Test
Intervention Name(s)
Physical Examination
Intervention Description
All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
Intervention Type
Diagnostic Test
Intervention Name(s)
Vital Signs
Intervention Description
Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
Intervention Type
Diagnostic Test
Intervention Name(s)
Blood Tests
Intervention Description
All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides). 5 ml of blood (equals to 1 spoon) will be taken for each test.
Intervention Type
Diagnostic Test
Intervention Name(s)
Urine Pregnancy Test
Intervention Description
Urine pregnancy test will be performed during the screening visit (for WOCBP).
Intervention Type
Diagnostic Test
Intervention Name(s)
Abdominal Ultrasound imaging
Intervention Description
All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
Intervention Type
Other
Intervention Name(s)
EuraHS-QoL
Other Intervention Name(s)
(hernia-specific European Hernia Society Quality of Life Questionnaire)
Intervention Description
patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
Intervention Type
Other
Intervention Name(s)
Visual Analouge Scale (VAS)
Intervention Description
A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
Intervention Type
Diagnostic Test
Intervention Name(s)
Clinical evaluation for hernia recurrence and clinical bulging
Intervention Description
The procedure includes: Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT. SAE's and SADE's evaluation of the seroma. Taking a photograph of the surgery area without disclosing the subject's identity.
Primary Outcome Measure Information:
Title
Adverse events assesments
Description
Overall rate of Serious Adverse Events and serious adverse device effects (SADE) related to study product up to hospital discharge and up to the 30th post-operative day.
Time Frame
up to 30 days
Secondary Outcome Measure Information:
Title
Hernia recurrence rate
Description
Hernia recurrence rate (Investigator confirmed hernia recurrence on physical examination or imaging).
Time Frame
up to 12 months
Title
Patient satisfaction
Description
2. Patient satisfaction and function as assessed by the European Hernia Society Quality of life questionnaire (EuraHS-QoL). score range : 0-180 pts; higher score means high pain and discomfort levels.
Time Frame
up to 14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years. Patient desires an elective surgical repair. Patient is able to provide an informed consent. Diagnosis of a primary or secondary ventral hernia, with a fascial defect of width no more than 5 cm width in size on clinical examination or imaging scan. Body mass index (BMI) of 20-40 kg/m2. Candidate for laparoscopic repair based on the operating surgeon's assessment. Exclusion Criteria: Exclusion criteria 1. Diagnosis of concomitant abdominal wall defect(s) contiguous with ventral hernia. 2. Patient in need of concomitant non-hernia repair surgical procedure(s). 3. Patient in need of emergent ventral hernia repair for complications such as incarceration, intestinal obstruction or strangulation. 4. The patient desires hernia repair using a technique other than that consistent with the study. 5. Patient has loss of domain as assessed on physical examination or CT scan. 6. Patient has a history of an abdominal aortic aneurysm repair. 7. Patient has a severe co-morbid condition likely to limit survival to less than 2 years. 8. Patient was treated with chemotherapy in the past 6 months. 9. Patient was treated with steroids in the past 6 months. 10. Patient with known collagen disorder. 11. Clean contaminated/contaminated or dirty surgical field. 12. Patient is pregnant or intends to become pregnant during the study period. 13. Patient has ascites on physical examination or CT scan. 14. Patient has liver failure. 15. Patient undergoing dialysis treatment. 16. Patient has a wound-healing disorder. 17. Patient has an untreated coagulation disorder or is on anti-coagulant therapy not managed peri-operatively with the advice or supervision of a hematologist. 18. Patient with autoimmune disorder requiring more than 10 mg of corticosteroid daily. 19. Patient who is immunocompromised (including a diagnosis of HIV/AIDS, organ transplant, or receiving chemo- or radiation therapy. 20. Patient in need of concomitant surgical procedures other than indicated in the protocol as acceptable. 21. Non-compliance with the study protocol. 22. Patient requests to exit the study. 23. Prior radiotherapy. 24. Active malignancy for at least 2 years. 25. Patients has Diastasis recti more than 4cm×4cm size
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nadia MD Lisovoder
Phone
+972529573063
Email
nadyal@galilee-cbr.com
Facility Information:
Facility Name
Hillel Yaffe Medical Center
City
Hadera
State/Province
Central District
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Nadav Nevo
Phone
+972527360023
Email
nadavn@tlvmc.gov.il
Facility Name
Barzilai Medical Center
City
Ashkelon
State/Province
Southern District
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Gil Ohana
Phone
+972505044441
Email
gilo@bmc.gov.il

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Laparoscopic Ventral Hernia Repair With Routine Defect Closure Using Su2ura® Approximation Device

We'll reach out to this number within 24 hrs